Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223840 · ClinicalTrials.gov registry record · Phase 2
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
A Phase 2 study of Smoking, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
- 20
- Study locations
NCT07223840: Recruiting Phase 2 study of Smoking, sponsored by Eli Lilly and Company.
NCT07223840 is a Phase 2 study of Smoking that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 222 participants, below the 453-participant average among 123 other Smoking trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07223840, a Phase 2 study of Smoking, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit. Study participation will last approximately 34 weeks with up to 17 study visits, which includes a 2-week screening period, 24-week treatment period, 8-week safety follow-up period. .
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Brenipatide
Study Locations (20)
Florida
- Hillcrest Medical Research - DeLand
- TecTum Research - Hollywood
- K2 Medical Research ORLANDO - Maitland
- GTL Medical & Research Group - Miami
Texas
- FutureSearch Trials of Dallas - Dallas
- NextStage Clinical Research_Houston (07) -Menninger Clinic - Houston
- The University of Texas Health Science Center at Houston - Houston
Other
- Beijing Chaoyang Hospital, Capital Medical University - Beijing
- Beijing Anding Hospital - Affiliated Capital University of Medical Science - Beijing
- Sichuan Provincial People's Hospital - Chengdu
Arkansas
- Woodland Research Northwest - Rogers
Georgia
- North Georgia Clinical Research - Woodstock
Michigan
- Revival Research Institute, LLC - Dearborn
Missouri
- Arch Clinical Trials - St Louis
Nevada
- Vector Clinical Trials - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
What NCT07223840 shows while recruiting
NCT07223840 is an interventional study that assigns participants to a tested intervention. The registered 222 participants enrollment target is mid-sized for trials with a published cap, below the 453-participant average among 123 other Smoking trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Smoking appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07223840 names 20 study sites across 13 states, led by Florida, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT07223840 about?
NCT07223840 is a clinical study titled "A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse". This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit. Study participation will last approximately 34 weeks with up to 17 study visits, which includes a 2-week screening period, 24-...
What is the current status of trial NCT07223840?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2025-11-03. Estimated completion is 2027-02.
What conditions does trial NCT07223840 study?
This clinical trial studies the following conditions: Smoking.
What interventions are being tested in trial NCT07223840?
The interventions under investigation include: Placebo (DRUG), Brenipatide (DRUG).
Who is sponsoring clinical trial NCT07223840?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223840 being conducted?
This trial has 20 study locations across Arkansas, Florida, Georgia, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07223840's enrollment target sits among peer trials
222 54th of 123 higher than 70 of 123 other Smoking trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence
RECRUITING · Phase 2
-
App for Reducing Cravings to Smoke
RECRUITING · Phase 2
-
Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava
ACTIVE NOT RECRUITING · Phase 2
-
Proactive Health Intervention for Tobacco Users (Get PHIT)
COMPLETED · Phase 2
-
Computer-Assisted Intervention for Smoking During Pregnancy
COMPLETED · Phase 2
-
Oxidative Stress and Vitamin E Requirements
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
- NCT05605574 · 222 participants · NA
Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI